

Date: 25.01.2025

To
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (E), Mumbai – 400 051
NSE Scrip Symbol: SAILIFE

To
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001
BSE Scrip Code: 544306

Dear Sir/ Madam,

Sub: Information about proposed capacity addition

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby submit the details as required under Para B of Part A of Schedule III of the Regulations read with Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

No	Particulars	Details
1	Existing capacity	The Company has entered into a long-term lease
2	Existing capacity utilization	agreement for acquiring an area of 1.21 acres of land
3	Proposed capacity addition	along with certain building structures in Shamirpet,
4	Period within which the proposed capacity is to be added	Hyderabad at an upfront investment of approximately Rs. 15 Crs. The Company plans to create R&D facility on the said leased land which will augment the existing Unit II Hyderabad Facility.
5	Investment required	
6	Mode of financing	The above investment will be funded from internal
7	Rationale.	accruals. The proposed facility is expected to be partially operational in Q4 of financial year ending March 2026.

We request you to take note of the same and oblige.

This is for your information and records.

Thank you.

For Sai Life Sciences Limited

Runa Karan

Company Secretary & Compliance Officer

Membership No.: A13721

Sai Life Sciences Limited (CIN: U24110TG1999PLC030970)